ILDONG Bioscience

Based in South Korea, ILDONG Bioscience manufactures biopharmaceutical products focusing on health and wellness, particularly in dietary supplements and innovative biotechnology solutions. ILDONG Bioscience, established in 2016 in Pyeongtaek, South Korea, specializes in biopharmaceuticals. In September 2021, the company raised KRW 20 billion in a Pre-IPO funding round, with investors including KB Securities and NH Investment & Securities. The firm has engaged in a single deal to date, with a current valuation of KRW 100 billion.

The CEO is Jang-hwi Lee. ILDONG Bioscience specializes in developing and distributing biopharmaceutical products that enhance health and wellness. Their core offerings include innovative dietary supplements and health-related products that address various health issues, such as immune support and digestive health. The company serves healthcare professionals, pharmacies, and health-conscious consumers across South Korea, Japan, and the United States, emphasizing product efficacy and safety through rigorous research and development efforts.

In the most recent fiscal year 2024, ILDONG Bioscience generated revenue of KRW 17,468,271. 20 and an EBITDA of KRW 1,585,562. 40. The company's revenue model is primarily B2B, relying on partnerships with healthcare providers, retailers, and wholesalers to distribute their products through pharmacies and health food stores.

Following the Pre-IPO funding round in September 2021, ILDONG Bioscience is focused on expanding its portfolio of biopharmaceutical products. Plans include developing new dietary supplements aimed at emerging health trends, with specific launches planned for 2025. The company aims to penetrate additional markets in Southeast Asia and Europe by 2026, leveraging recent funding to enhance R&D and distribution capabilities.